Comanche secures $75M to test preeclampsia siRNA in PhII, adds Scott Gottlieb to board
17 Jan 2024
Comanche Biopharma, an siRNA biotech created by veterans of The Medicines Company, has reeled in a $75 million Series B to test its drug candidate for preeclampsia, a pregnancy complication that impacts millions of women each year.
The Concord, MA-based biotech also said former FDA Commissioner Scott Gottlieb has joined its board in conjunction with announcing the oversubscribed round from New Enterprise Associates (NEA), Atlas Venture, GV, F-Prime Capital, Lilly Asia Ventures and Longview Healthcare Ventures. Gottlieb, a partner at NEA, will be joined on the board by Atlas partner David Grayzel, the company said Wednesday.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.